Antiplatelet therapy in acute coronary syndromes: the emergency physician's perspective

Area of Science:

• Cardiology
• Pharmacology

Background:

• Platelets are crucial in coronary thrombosis following atherosclerotic plaque rupture.
• Inhibiting platelet activity is fundamental in managing acute coronary syndromes (ACS).

Purpose of the Study:

• To evaluate the efficacy and risks of antiplatelet therapies in ACS patients.
• To inform clinical decisions regarding clopidogrel and glycoprotein (GP) IIb/IIIa inhibitors in the emergency department.

Main Methods:

• Review of current evidence on clopidogrel and GP IIb/IIIa inhibitors in ACS management.
• Analysis of benefits versus bleeding risks, particularly concerning subsequent coronary artery bypass graft surgery.

Main Results:

• Clopidogrel combined with aspirin reduces recurrent ischemic events in ACS patients and assists percutaneous coronary intervention.
• A potential for increased bleeding complications exists in patients requiring urgent coronary artery bypass graft surgery after clopidogrel therapy.
• Withholding antiplatelet therapy 3-5 days before surgery may minimize risks.
• Intravenous GP IIb/IIIa inhibitors are beneficial in percutaneous coronary intervention and high-risk non-ST-segment elevation ACS.

Conclusions:

• The decision to initiate clopidogrel or GP IIb/IIIa inhibitor therapy in ACS patients presenting to the emergency department must be individualized.
• Balancing the benefits of antiplatelet therapy against the risks of bleeding complications, especially before potential surgery, is critical.